OncoChip

Price: 500 €
Turnaround time: 10 working days (monday to friday)

OncoChip®  studies the DNA from whole blood or bone marrow, hybridized to a genomic microchip in one step, and allows the identification of:

  • Copy-Number Variation (CNV) in any region of the chromosome (Whole Genome).
  • Loss Of Heterozygosity (LOH).

For a definitive diagnosis of certain hematological malignancies, it can simultaneously require the study of karyotype and FISH, and because of its high resolution, the arrays allow the confluence of both techniques.

OncoChip®: CGH arrays of oligonucleotide probes + SNPs

Benefits over conventional techniques:

  • Higher resolution
    Over conventional karyotypes with 5-10Mb resolution, the 750K Affymetrix CytoScan arrays with 550,000 oligonucleotide probes and 200,000 SNPs probes allow the detection of genetic alterations to a resolution of 100kb.
  • Increased diagnostic capability
    Classical karyotypes require cropping that can be studied at metaphase and a growth failure may give inconclusive results. The CGH/SNPs arrays only require genetic material without having a growing culture.

Benefits over other arrays:

OncoChip® as it contains SNPs probes, allows the detection of other alterations that are not only detected in oligonucleotide probes:

  • Polyploidy situations such as triploidy, tetraploidy, etc. 
  • Detection of clonal or mosaicism abnormalities above 20%. 
  • Uniparental Disomy (UPD): two identical chromosomes. 
  • Detection of LOH rich regions: these regions are increased in cell lines with oncological disorders.

Recommendation:

Considering that this method does not detect balanced rearrangements, the hematologic malignancies that are best to deal with this technology are the studies of alterations in CLL (Chronic Lymphocytic Leukemia) and MDS (Myelodysplastic Syndromes), which allows the simultaneous detection of various alterations, putting by several FISH studies. It is recommended to use it for the study of ALL (Acute Lymphoblastic Leukemia), AML (Acute Myelogenous Leukemia) and MM (Multiple Myeloma) in cases of karyotype failure.